PharmaCyte’s Innovative Platform Now Set to Target Multiple Deadly CancersRecent company news is a strong reminder that the potential value of the PharmaCyte Biotech (OTCQB – PMCB - $0.07 – Spec Buy) Cell-in-a-Box® platform technology is in the billions since it has proven to be effective in treating varying forms of cancer in preclinical and clinical tests. In fact, the Company’s platform could be potentially used to treat over 265,000 new patients suffering from varying forms of abdominal cancer and the 232,000 new patients diagnosed with breast cancer each year. Abdominal Cancers According to the American Cancer Society, hundreds of thousands of new cases of abdominal cancers in the U.S. are diagnosed annually. These include but are not limited to: Colorectal: 132,000 Liver: 62,000 Pancreatic: 49,000 Ovarian: 22,000 To date, PharmaCyte’s live cell encapsulation technology, known as “Cell-in-a-Box®”, plus low-dose ifosfamide has successfully completed mid-stage clinical trials in pancreatic cancer. PharmaCyte could be just months away from a pre-IND meeting with the FDA to discuss plans for the next stage of clinical trials. Leveraging the solid results from completed trials and studies with PharmaCyte’s platform technology, PharmaCyte initiated preclinical studies designed to determine the effectiveness of Cell-in-a-Box® plus ifosfamide therapy in delaying the accumulation of malignant ascites fluid in the abdomen of mice with abdominal tumors. PharmaCyte’s initial series of preclinical studies were conducted with mice that had been inoculated with a human ovarian cancer. The data is being used as a foundation for future studies on other tumor types. For example, the results from PharmaCyte’s initial series of studies are now being used in connection with new colon cancer studies that may prove to be effective in developing a treatment that delays the production of malignant ascites fluid in cancer patients. In fact, the new study is based upon the results of previous work using this same model system that was performed by Dr. Matthias Löhr, the Chairman of PharmaCyte’s Scientific Advisory Board, and his colleagues at the University of Heidelberg, Germany. The results of the previous study were reported in the scientific publication Cancer Gene Therapy in 2006. PharmaCyte hopes to replicate the earlier study results which demonstrated that a combination of the Cell-in-a-Box® capsules and ifosfamide is effective in treating the spread of colon cancer that was caused by malignant ascites fluid. This fluid is produced by abdominal cancers and is largely responsible for the spread of cancer cells from the original tumor to other sites in the peritoneal cavity. According to management, if successful, PharmaCyte will have developed a treatment that will help combat the spread of abdominal tumors and reduce the suffering of cancer patients from the production of ascites fluid within the abdominal cavity. Breast Cancer PharmaCyte’s platform technology plus low-dose ifosfamide has also achieved enviable success in efforts to develop a treatment for one of the most high profile cancers that are attributed to well over 200,000 new cases annually - breast cancer. In fact, the medical journal PLOS One published a study in which a Phase I/II clinical trials was conducted in dogs with spontaneously occurring mammary tumors which produced stellar results. (http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0102061). It should be noted that this animal model is closely related to the development of breast cancer in humans. As one might expect, the study results were remarkably similar to the earlier human Phase I/II pancreatic cancer trial using PharmaCyte’s platform technology. In the trial, which included 16 female dogs, cyclophosphamide was chosen as the pro-drug instead of the pro-drug the ifosfamide used in the earlier pancreatic trials. That is because cyclophosphamide is a standard chemotherapeutic agent used in combination with others for the treatment of mammary cancer in dogs as well as breast cancer in humans. Since both cyclophosphamide and ifosfamide are “sister” pro-drugs and are converted to their cancer-killing forms in the same way, the same type of encapsulated live cells were used in both the pancreatic and mammary cancer studies. As in the human pancreatic cancer trials, the capsules were well tolerated in the mammary cancer trials, with no major safety issues. Importantly, far greater tumor shrinkage was observed in those dogs treated with encapsulated cells as well as the pro-drug versus those receiving cyclophosphamide alone. Interestingly, prior to receiving approval for Abraxane as a treatment for pancreatic cancer, Celgene (NASDAQ – CELG) was awarded FDA approval to use the treatment for breast cancer. Since breast cancer is easier to treat and has a much higher survival rate than pancreatic cancer, it is conceivable that if PharmaCyte is successful in garnering FDA approval for pancreatic cancer, a breast cancer treatment approval could be a slam dunk. The bottom line? If the favorable data from previous trials and studies for multiple cancer indications are any indication of potential future results, PharmaCyte’s novel approach could emerge as one of the most effective and diverse cancer treatment platforms in the market for solid tumors of all kinds and could be worth billions of dollars. For more information, refer to our previous sponsored PMCB Reports, Updates and Hot Topic Articles by visiting http://www.GoldmanResearch.com/ You Might Also Like
Senior Analyst: Robert Goldman Rob Goldman founded Goldman Small Cap Research in 2009 and has over 20 years of investment and company research experience as a senior research analyst and as a portfolio and mutual fund manager. During his tenure as a sell side analyst, Rob was a senior member of Piper Jaffray's Technology and Communications teams. Prior to joining Piper, Rob led Josephthal & Co.'s Washington-based Emerging Growth Research Group. In addition to his sell-side experience Rob served as Chief Investment Officer of a boutique investment management firm and Blue and White Investment Management, where he managed Small Cap Growth portfolios and The Blue and White Fund. Analyst Certification I, Robert Goldman, hereby certify that the view expressed in this research report accurately reflect my personal views about the subject securities and issuers. I also certify that no part of my compensation was, is, or will be, directly or indirectly, related to the recommendations or views expressed in this research report. Disclaimer This Microcap Hot Topics Article was prepared for informational purposes only.
Goldman Small Cap Research, (a division of Two Triangle Consulting Group, LLC) produces research via two formats: Goldman Select Research and Goldman Opportunity Research. The Select format reflects the Firm’s internally generated stock ideas along with economic and stock market outlooks. Opportunity Research reports, updates and Microcap Hot Topics articles reflect sponsored (paid) research but can also include non-sponsored microcap research ideas that typically carry greater risks than those stocks covered in the Select Research category. It is important to note that while we may track performance separately, we utilize many of the same coverage criteria in determining coverage of all stocks in both research formats. Research reports on profiled stocks in the Opportunity Research format typically have a higher risk profile, and may offer greater upside. In 2015, Goldman Small Cap Research has been compensated by a third party in the amount of $22,000 for a research subscription service including a report, updates, and a series of articles. Our analysts are responsible only to the public, and are paid in advance to eliminate pecuniary interests, retain editorial control, and ensure independence. Analysts are compensated on a per report basis and not on the basis of his/her recommendations. Goldman Small Cap Research is not affiliated in any way with Goldman Sachs & Co. The information used and statements of fact made have been obtained from sources considered reliable but we neither guarantee nor represent the completeness or accuracy. Goldman Small Cap Research did not make an independent investigation or inquiry as to the accuracy of any information published by the Company, or other firms. Goldman Small Cap Research relied solely upon information published by the Company through its filings, press releases, presentations, and through its own internal due diligence for accuracy and completeness. Statements herein may contain forward-looking statements and are subject to significant risks and uncertainties affecting results. Separate from the factual content of our articles about the Company, we may from time to time include our own opinions about the Company, its business, markets and opportunities. Any opinions we may offer about the Company are solely our own, and are made in reliance upon our rights under the First Amendment to the U.S. Constitution, and are provided solely for the general opinionated discussion of our readers. Our opinions should not be considered to be complete, precise, accurate, or current investment advice. Such information and the opinions expressed are subject to change without notice. A Goldman Small Cap Research report or article is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed. This publication does not take into account the investment objectives, financial situation, or particular needs of any particular person. This publication does not provide all information material to an investor’s decision about whether or not to make any investment. Any discussion of risks in this presentation is not a disclosure of all risks or a complete discussion of the risks mentioned. Neither Goldman Small Cap Research, nor its parent, is registered as a securities broker-dealer or an investment adviser with FINRA, the U.S. Securities and Exchange Commission or with any state securities regulatory authority. ALL INFORMATION IN THIS REPORT IS PROVIDED “AS IS” WITHOUT WARRANTIES, EXPRESSED OR IMPLIED, OR REPRESENTATIONS OF ANY KIND. TO THE FULLEST EXTENT PERMISSIBLE UNDER APPLICABLE LAW, TWO TRIANGLE CONSULTING GROUP, LLC WILL NOT BE LIABLE FOR THE QUALITY, ACCURACY, COMPLETENESS, RELIABILITY OR TIMELINESS OF THIS INFORMATION, OR FOR ANY DIRECT, INDIRECT, CONSEQUENTIAL, INCIDENTAL, SPECIAL OR PUNITIVE DAMAGES THAT MAY ARISE OUT OF THE USE OF THIS INFORMATION BY YOU OR ANYONE ELSE (INCLUDING, BUT NOT LIMITED TO, LOST PROFITS, LOSS OF OPPORTUNITIES, TRADING LOSSES, AND DAMAGES THAT MAY RESULT FROM ANY INACCURACY OR INCOMPLETENESS OF THIS INFORMATION). TO THE FULLEST EXTENT PERMITTED BY LAW, TWO TRIANGLE CONSULTING GROUP, LLC WILL NOT BE LIABLE TO YOU OR ANYONE ELSE UNDER ANY TORT, CONTRACT, NEGLIGENCE, STRICT LIABILITY, PRODUCTS LIABILITY, OR OTHER THEORY WITH RESPECT TO THIS PRESENTATION OF INFORMATION. For more information, visit our Disclaimer: www.goldmanresearch.com |
